Mankind Pharma Ltd IPO

Incorporated in 1983, Kolkata-based Tarsons Products manufactures laboratory products that are used in various research organisations, pharmaceutical companies, academia institutes, hospitals and diagnostic centres.

The company plans to go public and here’s all you need to know about this IPO.

Here’s the consolidated financial information for the last three years:

• scaled domestic focused business with potential for further growth;
• growing faster than the rate of the IPM with a focus on volume-led growth;
• diversified portfolio with market leading rankings across key therapeutic areas;
• established and growing consumer healthcare franchise with brand recall;
• leveraged its corporate brand to build and scale brands;

• The company is subject to extensive government regulations which are also subject to change. If the company fail to comply with the applicable regulations prescribed by the governments and the relevant regulatory agencies, its business, financial condition, cash flows and results of operations will be adversely affected.
• The company is required to obtain, maintain or renew its statutory and regulatory approvals, licenses, and registrations to operate its business.
• Any disruption, slowdown or shutdown in its manufacturing or R&D operations could adversely affect its business, financial condition, cash flows and results of operations.
• The company inability to accurately forecast demand for its products and manage the company inventory may have an adverse effect on its business, financial condition, cash flows and results of operations.
• Any failure to maintain and enhance, or any damage to, its brands, product image or reputation could adversely affect the market recognition of, and trust in, the company products.

• Increase Covered Market presence including in chronic therapeutic areas
• Focus on increasing penetration in metro and Class I cities
• Focus on building alternative channels for growth
• Grow its consumer healthcare business
• Continue to develop and invest in digital platforms to enhance doctor engagement